GLP-1 Microdosing for Maintenance: The 0.05 mg Semaglutide Protocols Researchers Are Discussing

Important Notice: This article is intended exclusively for scientific information and research purposes. All substances mentioned are not intended for human consumption. The content is not medical advice. No dosing recommendation is given. Always consult qualified professionals before using peptides.

Introduction: Why Microdosing Hit the Mainstream in April 2026

In April 2026 the term "GLP-1 microdosing" went from a niche research curiosity to mainstream coverage. Tufts Medicine published an explainer titled "Microdosing GLP-1s: Your Questions Answered" on its public health portal. Cleveland Clinic followed with a "Health Essentials" piece on the same topic. NewYork-Presbyterian and other major academic centres ran similar consumer-facing articles within the same fortnight. None of these institutions endorsed microdosing. All three flagged the same point: people who finished a course of semaglutide or tirzepatide are looking for a way to stay at their new weight without the cost, side effects and supply pressure of a full therapeutic dose, and they are doing it whether or not the literature has caught up.

The term "microdose" is borrowed loosely from psychedelic research and lacks an agreed clinical definition. In community discussions on r/Tirzepatide and r/Semaglutide it usually refers to weekly or biweekly doses one quarter to one tenth of the labeled maintenance dose. For semaglutide that means 0.05 mg to 0.25 mg, compared with the 1.7 mg or 2.4 mg licensed for chronic weight management. The interest is real, the data are sparse, and the practical questions are mostly about reconstitution math, dosing intervals and how to interpret an absent therapeutic signal. This article walks through the current evidence and the protocols being discussed, strictly as a research overview.

What Is GLP-1 Microdosing?

A microdose, in this context, is a dose of a GLP-1 receptor agonist that is well below the labeled therapeutic dose for either type 2 diabetes or chronic weight management. There is no consensus boundary. Tufts Medicine describes microdosing as "any dose below the FDA approved one." Cleveland Clinic notes that some users start at 0.05 mg semaglutide weekly, roughly one fifth of the standard 0.25 mg starter dose, while others stop ramping at 0.5 mg.

For orientation, the labeled regimens for semaglutide in obesity look like this:

Phase	Dose	Frequency
Start	0.25 mg	Weekly
Escalation	0.5 mg, 1.0 mg, 1.7 mg	Weekly
Maintenance	2.4 mg	Weekly

Microdose protocols discussed in the community sit one to two log units below the maintenance dose:

Discussed protocol	Dose	Frequency
Very low microdose	0.05 mg	Every 7 to 14 days
Low microdose	0.10 mg	Every 7 to 10 days
Moderate microdose	0.25 mg	Every 7 to 14 days

These are not recommendations. They are the numbers most often quoted in user reports. None are taken from a published trial protocol.

For background on the molecule itself see Semaglutide: Science 2026 and the broader GLP-1 Agonists Compared.

Why People Are Doing It

The most cited motivation is post-loss maintenance. Phase 3 trials of semaglutide (STEP) and tirzepatide (SURMOUNT) consistently show weight regain within 12 months after discontinuation. The STEP 4 extension of semaglutide and the SURMOUNT-4 retreatment study both implied that ongoing exposure to a GLP-1 signal is what holds the weight off. People who have lost 15 to 25 percent of their body weight and do not want to regain it are looking for the smallest exposure that still produces a satiety signal.

Three other motivations come up repeatedly:

Side effect minimisation. Nausea, constipation and reflux are dose dependent. Users who tolerated 1.0 mg poorly often report that 0.10 to 0.25 mg is asymptomatic.

Cost and supply. A 5 mg semaglutide vial used at 0.10 mg per week lasts roughly a year. The same vial at 2.4 mg per week lasts two weeks. The economics of microdosing are a major part of the appeal, especially in 2026 when supply of branded semaglutide and tirzepatide remains tight.

Post cycle stability. Some users describe a "step down" from full therapeutic dosing during the last four to twelve weeks of a course, with the goal of arriving at a sustainable maintenance level rather than a hard stop.

For a comparison of the three leading molecules see Retatrutide vs. Tirzepatide vs. Semaglutide.

Typical Research Protocols Seen in Community Reports

The protocols below are summarised from public Reddit threads, forum posts and the explainers from Tufts Medicine, Cleveland Clinic and IvyRx. They are descriptive, not prescriptive. None come from a randomised trial.

Frequency: weekly, every 10 days, or every 14 days

Semaglutide has a half life of approximately 165 hours, roughly seven days. A weekly dose maintains a near steady state. Users running 0.05 to 0.10 mg weekly report a mild but consistent appetite signal. Some shift to every 10 or 14 days once they feel stable, on the rationale that they want intermittent reinforcement rather than continuous suppression. The pharmacokinetic case for biweekly dosing is weaker because plasma levels fall to roughly one quarter of peak by day 14.

Dose ramping in reverse

Users coming off a full therapeutic course often describe a stepwise reduction: from 2.4 mg to 1.7 mg, then 1.0 mg, then 0.5 mg, then 0.25 mg, then 0.10 mg, holding each step for two to four weeks. The aim is to identify the lowest dose at which appetite signal is preserved. This is sometimes called "finding your floor."

What Tufts and Cleveland Clinic actually say

Both institutions stop short of endorsing microdosing. Tufts Medicine notes that there is no clinical evidence that microdosing produces meaningful weight loss, that compounded versions sold for microdosing are not FDA reviewed, and that the practice is "not without risk." Cleveland Clinic frames the topic the same way: it is something patients are doing, the data do not yet exist, and any deviation from the label is between a patient and their physician. These articles are evidence of mainstream interest, not endorsements of a protocol.

What We Don't Know Yet

The honest answer is "almost everything." There are no completed randomised trials of a 0.05 mg or 0.10 mg semaglutide maintenance arm. The published Phase 3 programmes (STEP 1 to 8, SURMOUNT 1 to 5) studied the labeled doses against placebo, not microdoses against placebo or against full dosing. The closest analogue is the STEP 4 trial, which showed that continuing 2.4 mg sustained weight loss while switching to placebo led to regain. STEP 4 says nothing about whether 0.10 mg would have been enough.

Open questions include:

The dose response curve of GLP-1 agonists below 0.25 mg is largely uncharacterised in humans.
Whether intermittent dosing (every 14 days) preserves the central appetite effect or only the peripheral effects on gastric emptying is unknown.
Long term safety at low chronic doses has not been studied separately. The Phase 3 safety database is at therapeutic doses.
Compounded "microdose" products, often sold online in 2026, are not FDA reviewed and have shown variable potency in independent assays.

The conservative reading: microdose maintenance is a plausible hypothesis with no controlled evidence behind it.

Reconstitution and Storage for Microdose Research

The single most common practical question in community threads is how to draw 0.05 mg accurately from a 5 mg vial. The math is straightforward but the volumes are small and easy to get wrong.

Worked example with a 5 mg vial

Reconstitute 5 mg of lyophilised semaglutide with 2.5 mL of bacteriostatic water. The vial now contains 5 mg / 2.5 mL = 2 mg/mL.

Target dose	Volume to draw	On a U-100 insulin syringe
0.05 mg	0.025 mL	2.5 units
0.10 mg	0.050 mL	5 units
0.25 mg	0.125 mL	12.5 units
0.50 mg	0.250 mL	25 units

A U-100 insulin syringe has 100 units per millilitre. Each "unit" mark equals 0.01 mL.

If 2.5 units feels too small to read accurately, the alternative is to reconstitute with more bacteriostatic water. Reconstituting 5 mg with 5 mL gives 1 mg/mL, so a 0.05 mg dose becomes 0.05 mL or 5 units, which is easier to draw. The trade-off is a larger injected volume. For accurate microdose work the volume you can comfortably read on your syringe should drive the dilution, not the other way around.

For the underlying mechanics see BPC-157 Reconstitution Guide, which covers the same procedure in detail.

Storage of the reconstituted vial

Reconstituted semaglutide is generally stored refrigerated at 2 to 8 degrees Celsius. At microdose volumes a single vial may be in use for several months. Sterility, not chemical degradation, becomes the dominant concern. Bacteriostatic water (0.9 percent benzyl alcohol) is preferred over plain sterile water for that reason, and the rubber stopper should be wiped with isopropanol before each draw. See Peptide Storage Guide for shelf life data and temperature sensitivity.

Stack Considerations

A second pattern visible in 2026 community reports is the "microswitch": users alternating between a low dose of semaglutide and a low dose of tirzepatide on different weeks, on the theory that the GIP component of tirzepatide adds a different satiety axis. There is no published rationale for this. The pharmacokinetics of both molecules are similar enough that the practice is essentially intermittent dual agonism at low doses. For the mechanistic background see Tirzepatide: Science 2026.

A third stack discussed is microdose semaglutide alongside an oral appetite modulator or a non-incretin metabolic peptide. None of these combinations have been studied. The base rate for unexpected interactions in low-evidence stacks is high. Researchers planning combination protocols should treat them as exploratory.

Conclusion and Takeaways

Microdose GLP-1 maintenance is the loudest open question in metabolic peptide research in spring 2026. Mainstream coverage from Tufts Medicine, Cleveland Clinic and others marks it as a topic that the medical establishment can no longer ignore, but their explainers are not endorsements. The user-driven protocols centre on 0.05 mg to 0.25 mg semaglutide weekly or biweekly, derived empirically from the post-cycle experience of people who do not want to regain weight. The evidence base for these specific doses is essentially zero. The reconstitution math is the most reliable part of the discussion: a 5 mg vial reconstituted with 2.5 mL gives 2 mg/mL, and 0.05 mg is 2.5 units on a U-100 syringe.

Key points

Microdose protocols use roughly 2 to 10 percent of the labeled maintenance dose
Mainstream coverage in April 2026 reflects interest, not endorsement
No randomised data exist for these dose ranges
Reconstitution accuracy and sterility dominate the practical considerations
Compounded microdose products are not FDA reviewed and vary in potency

For laboratory researchers, the gap between hypothesis and evidence here is large enough that any protocol design should explicitly state the absence of controlled data and prefer dose response work over fixed low-dose comparisons.

Sources

Tufts Medicine. "Microdosing GLP-1s: Your Questions Answered." April 2026. https://www.tuftsmedicine.org/about-us/news/microdosing-glp-1s-your-questions-answered
Cleveland Clinic Health Essentials. "Microdosing GLP-1." April 2026. https://health.clevelandclinic.org/microdosing-glp-1
IvyRx. "GLP-1 Microdosing Schedule." 2026. https://www.ivyrx.com/blog/glp-1-microdosing-schedule
Rubino D, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4 Trial." JAMA. 2021;325(14):1414-1425.
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM. 2021;384:989-1002.
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM. 2022;387:205-216.